3,177
Views
124
CrossRef citations to date
0
Altmetric
Review Article

The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol

, , , &
Pages 458-470 | Received 19 May 2012, Accepted 04 Jun 2012, Published online: 29 Jun 2012

References

  • Rubin BA, Giarman NJ. The therapy of experimental influenza in mice with antibiotic lactones and related compounds. Yale J Biol Med 1947; 19:1017–1022.
  • Giacomino NJ, Mc CE. On the toxic reactions of unsaturated lactones and their saturated analogs. Fed Proc 1947; 6:331.
  • Laborit H, Jouany JM, Gerard J, Fabiani F. Summary of an experimental and clinical study on a metabolic substrate with inhibitory central action: sodium 4-hydroxybutyrate. Presse Med 1960; 68:1867–1869.
  • Dekkers MPJ. Le glycol tétraméthylénique. Recl Trav Chim Pays Bas 1890; 9:92–102.
  • Bessman SP, Fishbein WN. Gamma-hydroxybutyrate, a normal brain metabolite. Nature 1963; 200:1207–1208.
  • Blumenfeld M, Harmel MH, Suntay RG. Sodium gamma-hydroxybutyric acid: a new anesthetic adjuvant. Anesth Analg 1962; 41:721–726.
  • Solway J, Sadove MS. 4-Hydroxybutyrate: a clinical study. Anesth Analg 1965; 44:532–539.
  • Wedin GP, Hornfeldt CS, Ylitalo LM. The clinical development of gamma-hydroxybutyrate (GHB). Curr Drug Saf 2006; 1:99–106.
  • Takahara J, Yunoki S, Yakushiji W, Yamauchi J, Yamane Y, Ofuji T. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 1977; 44:1014–1017.
  • Marwick C. Coma-inducing drug GHB may be reclassified. JAMA 1997; 227:1505–1506.
  • Nelson LS. Butanediol and ethanol: a reverse mickey finn? Int J Med Toxicol 2000; 3:2.
  • Rambourg-Schepens MO, Buffet M, Durak C, Mathieu-Nolf M. Gamma-butyrolactone poisoning and its similarities to gamma-hydroxybutyric acid: two case reports. Vet Hum Toxicol 1997; 39:234–235.
  • Knudsen K, Greter J, Verdicchio M, Cederquist T. GHB, GBL and butanediol poisonings—a serious problem in Western Sweden. Lakartidningen 2005; 102:3294–3296.
  • Knudsen K, Greter J, Verdicchio M. High mortality rates among GHB abusers in Western Sweden. Clin Toxicol (Phila) 2008; 46:187–192.
  • Knudsen K, Jonsson U, Abrahamsson J. Twenty-three deaths with gamma-hydroxybutyrate overdose in western Sweden between 2000 and 2007. Acta Anaesthesiol Scand 2010; 54:987–992.
  • Wood DM, Nicolaou M, Dargan PI. Epidemiology of recreational drug toxicity in a nightclub environment. Subst Use Misuse 2009; 44:1495–1502.
  • Liechti ME, Kupferschmidt H. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL): analysis of overdose cases reported to the Swiss Toxicological Information Centre. Swiss Med Wkly 2004; 134:534–537.
  • Rodgers J, Ashton CH, Gilvarry E, Young AH. Liquid ecstasy: a new kid on the dance floor. Br J Psychiatry 2004; 184:104–106.
  • Miró O, Nogué S, Espinosa G, To-Figueras J, Sánchez M. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol 2002; 40:129–135.
  • Liechti ME, Kunz I, Greminger P, Speich R, Kupferschmidt H. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend 2006; 81:323–326.
  • Camacho A, Matthews SC, Murray B, Dimsdale JE. Use of GHB compounds among college students. Am J Drug Alcohol Abuse 2005; 31:601–607.
  • Degenhardt L, Darke S, Dillon P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend 2002; 67:89–94.
  • Degenhardt L, Copeland J, Dillon P. Recent trends in the use of “club drugs”: an Australian review. Subst Use Misuse 2005; 40:1241–1256.
  • Harraway T, Stephenson L. Gamma hydroxybutyrate intoxication: the gold coast experience. Emerg Med (Fremantle) 1999; 11:45–48.
  • Dietze PM, Cvetkovski S, Barratt MJ, Clemens S. Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria. Med J Aust 2008; 188:709–711.
  • Robinson GM, Wardell JA. Gamma hydroxybutyric acid “fantasy”--drug of abuse. N Z Med J 2000; 113:65.
  • Theron L, Jansen K, Skinner A. New Zealand's first fatality linked to use of 1,4-butanediol (1,4-B, Fantasy): no evidence of coingestion or comorbidity. N Z Med J 2003; 116:U650.
  • Theron L, Jansen K, Miles J. Benzylpiperizine-based party pills’ impact on the Auckland City Hospital Emergency Department Overdose Database (2002–2004) compared with ecstasy (MDMA or methylene dioxymethamphetamine), gamma hydroxybutyrate (GHB), amphetamines, cocaine, and alcohol. N Z Med J 2007; 120:U2416.
  • Couper FJ, Thatcher JE, Logan BK. Suspected GHB overdoses in the emergency department. J Anal Toxicol 2004; 28:481–484.
  • Louagie HK, Verstraete AG, DeSoete CJ, Baetens DG, Calle PA. A sudden awakening from a near coma after combined intake of gamma-hydroxybutyric acid (GHB) and ethanol. J Toxicol Clin Toxicol 1997; 35:591–594.
  • Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. Ann Emerg Med 1998; 31:723–728.
  • Chin RL, Sporer KA, Cullison B, Dyer JE, Wu TD. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998; 31:716–722.
  • Van Sassenbroeck DK, De Neve N, De Paepe P, Belpaire FM, Verstraete AG, Calle PA, Buylaert WA. Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series. Clin Toxicol (Phila) 2007; 45:533–538.
  • Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001; 10:232–241.
  • Roberts DM, Smith MW, Gopalakrishnan M, Whittaker G, Day RO. Extreme gamma-butyrolactone overdose with severe metabolic acidosis requiring hemodialysis. Ann Emerg Med 2011; 58:83–85.
  • Munir VL, Hutton JE, Harney JP, Buykx P, Weiland TJ, Dent AW. Gamma-hydroxybutyrate: a 30 month emergency department review. Emerg Med Australas 2008; 20:521–530.
  • Wood DM, Warren-Gash C, Ashraf T, Greene SL, Shather Z, Trivedy C, . Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). QJM 2008; 101:23–29.
  • Galicia M, Nogue S, Miro O. Liquid ecstasy intoxication: clinical features of 505 consecutive emergency department patients. Emerg Med J 2011; 28:462–466.
  • Anderson IB, Kim SY, Dyer JE, Burkhardt CB, Iknoian JC, Walsh MJ, Blanc PD. Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003. Ann Emerg Med 2006; 47: 177–183.
  • Snead OC, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005; 352:2721–2732.
  • Ryan JM, Stell I. Gamma hydroxybutyrate—a coma inducing recreational drug. J Accid Emerg Med 1997; 14:259–291.
  • Centers for Disease Control and Prevention (CDC). Gamma hydroxy butyrate use—New York and Texas, 1995–1996. MMWR Morb Mortal Wkly Rep 1997; 46:281–283.
  • Schneidereit T, Burkhart K, Donovan JW. Butanediol toxicity delayed by preingestion of ethanol. Int J Med Toxicol 2000; 3:1.
  • Garrison G, Mueller P. Clinical features and outcomes after unintentional gamma hydroxybutyrate (GHB) overdose [abstract]. J Toxicol Clin Toxicol 1998; 35:503–504.
  • Stephens BG, Baselt RC. Driving under the influence of GHB? J Anal Toxicol 1994; 18:357–358.
  • Eckstein M, Henderson SO, DelaCruz P, Newton E. Gamma hydroxybutyrate (GHB): report of a mass intoxication and review of the literature. Prehosp Emerg Care 1999; 3:357–361.
  • Bosman IJ, Lusthof KJ. Forensic cases involving the use of GHB in The Netherlands. Forensic Sci Int 2003; 133:17–21.
  • Ferrara SD, Tedeschi L, Frison G, Rossi A. Fatality due to gamma-hydroxybutyric acid (GHB) and heroin intoxication. J Forensic Sci 1995; 40:501–504.
  • ElSohly MA, Salamone SJ. Prevalence of drugs used in cases of alleged sexual assault. J Anal Toxicol 1999; 23:141–146.
  • Hindmarch I, Brinkmann R. Trends in the use of alcohol and other drugs in cases of sexual assault. Hum Psychopharmacol Clin Exp 1999; 14:225–231.
  • Slaughter L. Involvement of drugs in sexual assault. J Reprod Med 2000; 45:425–430.
  • Hindmarch I, ElSohly M, Gambles J, Salamone S. Forensic urinalysis of drug use in cases of alleged sexual assault. J Clin Forensic Med 2001; 8:197–205.
  • Scott-Ham M, Burton FC. Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Clin Forensic Med 2005; 12:175–186.
  • Németh Z, Kun B, Demetrovics Z. The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review. J Psychopharmacol 2010; 24:1281–1287.
  • Fuller DE, Hornfeldt CS. From club drug to orphan drug: sodium oxybate (Xyrem) for the treatment of cataplexy. Pharmacotherapy 2003; 23:1205–1209.
  • Caputo F, Vignoli T, Maremmani I, Bernardi M, Zoli G. Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review. Int J Environ Res Public Health 2009; 6:1917–1929.
  • UNODC. World Drug Report. Vienna, Austria: United Nations Office on Drugs and Crime; 2011. http://www.unodc.org/documents/data-and-analysis/WDR2011/World_Drug_Report_2011_ebook.pdf. Accessed 18 April 2012. Vienna, Austria; 2011.
  • EMCDDA. GHB and its precursor GBL: an emerging trend case study. Thematic papers, European Monitoring Centre for Drugs and Drug Addiction. Available at: http://www.emcdda.europa.eu/publications/thematic-papers/ghb. Accessed 18 April 2012. Lisbon; 2008.
  • UNODC. Global Smart update, Volume 3: United Nations Office on Drugs and Crime; 2011. http://www.unodc.org/documents/scientific/Global_SMART_Update_2010_Vol.3-LowRes.pdf. Accessed 18 April 2012. Vienna, Austria; 2010.
  • ACC. Austrailan Crime Commission. Ilicit Drug Data Report (2010–2011). Available at: http://www.crimecommission.gov.au/publications/illicit-drug-data-report/illicit-drug-data-report-2010-11. Accessed 18 May 2012. Canberra City, Australia; 2011.
  • AIHW. Australian Institute of Health and Welfare: National Drug Strategy Household Survey report. Drug statistics series no. 25. Canberra, Australia; 2011.
  • Watson WA, Litovitz TL, Rodgers GC, Klein-Schwartz W, Youniss J, Rose SR, . 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21:353–421.
  • Bronstein AC, Spyker DA, Cantilena LR, Green JL, Rumack BH, Dart RC. 2010 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 28th Annual Report (Supplementary material). Clin Toxicol (Phila) 2011; 49:910–941.
  • Doherty JD, Hattox SE, Snead OC, Roth RH. Identification of endogenous gamma-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea-pig and rhesus-monkey brain. J Pharmacol Exp Ther 1978; 207:130–139.
  • Roth RH, Giarman NJ. Natural occurrence of gamma-hydroxybutyrate in mammalian brain. Biochem Pharmacol 1970; 19:1087–1093.
  • Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997; 51:337–361.
  • Hechler V, Weissmann D, Mach E, Pujol JF, Maitre M. Regional distribution of high-affinity gamma-[H-3] hydroxybutyrate binding-sites as determined by quantitative autoradiography. J Neurochem 1987; 49:1025–1032.
  • Hechler V, Gobaille S, Maitre M. Selective distribution pattern of gamma-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography. Brain Res 1992; 572:345–348.
  • Castelli MP, Mocci I, Langlois X, Gommeren W, Luyten W, Leysen JE, Gessa GL. Quantitative autoradiographic distribution of gamma-hydroxybutyric acid binding sites in human and monkey brain. Brain Res Mol Brain Res 2000; 78:91–99.
  • Snead OC. Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor. J Neurochem 2000; 75:1986–1996.
  • Hu RQ, Banerjee PK, Snead OC. Regulation of gamma-aminobutyric acid (GABA) release in cerebral cortex in the gamma-hydroxybutyric acid (GHB) model of absence seizures in rat. Neuropharmacology 2000; 39:427–439.
  • Howard SG, Feigenbaum JJ. Effect of gamma-hydroxybutyrate on central dopamine release in vivo. A microdialysis study in awake and anesthetized animals. Biochem Pharmacol 1997; 53:103–10.
  • Hechler V, Gobaille S, Bourguignon JJ, Maitre M. Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study. J Neurochem 1991; 56:938–944.
  • Hedner T, Lundborg P. Effect of gammahydroxybutyric acid on serotonin synthesis, concentration and metabolism in the developing rat brain. J Neural Transm 1983; 57:39–48.
  • Lason W, Przewlocka B, Przewlocki R. The effect of gamma- hydroxybutyrate and anticonvulsants on opioid peptide content in the rat brain. Life Sci 1983; 33 Suppl 1:599–602.
  • Gerra G, Caccavari R, Fontanesi B, Marcato A, Fertonani Affini G, Maestri D, . Flumazenil effects on growth hormone response to gamma-hydroxybutyric acid. Int Clin Psychopharmacol 1994; 9:211–215.
  • Addolorato G, Capristo E, Gessa GL, Caputo F, Stefanini GF, Gasbarrini G. Long-term administration of GHB does not affect muscular mass in alcoholics. Life Sci 1999; 65:PL191–PL196.
  • Snead OC. The gamma-hydroxybutyrate model of absence seizures: correlation of regional brain levels of gamma-hydroxybutyric acid and gamma-butyrolactone with spike wave discharges. Neuropharmacology 1991; 30:161–167.
  • Williams SR, Turner JP, Crunelli V. Gamma-hydroxybutyrate promotes oscillatory activity of rat and cat thalamocortical neurons by a tonic GABAB, receptor-mediated hyperpolarization. Neuroscience 1995; 66:133–141.
  • Palatini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, . Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993; 45:353–356.
  • Borgen LA, Okerholm R, Morrison D, Lai A. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol 2003;43:59–65.
  • Brenneisen R, Elsohly MA, Murphy TP, Passarelli J, Russmann S, Salamone SJ, Watson DE. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 2004; 28:625–630.
  • Helrich M, Mcaslan TC, Skolnik S, Bessman SP. Correlation of blood levels of 4-hydroxybutyrate with state of consciousness. Anesthesiology 1964; 25:771–775.
  • Abanades S, Farre M, Segura M, Pichini S, Barral D, Pacifici R, . Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci 2006; 1074:559–576.
  • Scharf MB, Lai AA, Branigan B, Stover R, Berkowitz DB. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 1998; 21:507–514.
  • Borgen LA, Okerholm RA, Lai A, Scharf MB. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. J Clin Pharmacol 2004; 44:253–257.
  • Ferrara SD, Zotti S, Tedeschi L, Frison G, Castagna F, Gallimberti L, . Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 1992; 34:231–235.
  • Ferrara SD, Tedeschi L, Frison G, Orlando R, Mazzo M, Zordan R, . Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. Eur J Clin Pharmacol 1996; 50:305–310.
  • Thai D, Dyer JE, Jacob P, Haller CA. Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther 2007; 81:178–184.
  • Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. Encephale 1980; 6:93–100.
  • Metcalf DR, Emde RN, Stripe JT. An EEG-behavioral study of sodium hydroxybutyrate in humans. Electroencephalogr Clin Neurophysiol 1966; 20:506–512.
  • Vree TB, Damsma J, van den Bogert AG, van den Kleijn E. Pharmocokinetics of 4-hydroxybutyric acid in man, rhesus monkey and dog. In: Frey R, ed. Neue Untersuchungen mit Gamma-Hydroxybuttersäure. Berlin: Springer-Verlag; 1978:21–39.
  • Lettieri JT, Fung HL. Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. J Pharmacol Exp Ther 1979; 208:7–11.
  • Lettieri J, Fung HL. Absorption and first-pass metabolism of 14C-gamma-hydroxybutyric acid. Res Commun Chem Pathol Pharmacol 1976; 13:425–437.
  • Pol W, Kleijn E, Lauw M. Gas chromatographic determination and pharmacokinetics of 4-hydroxybutrate in dog and mouse. J Pharmacokinet Biopharm 1975; 3:99–113.
  • van den Bogert AG, Vree TB, van den Kleijn E, Damsma J. Placental transfer of 4-hydroxybutyric acid in man. In: Frey R, ed. Neue Untersuchungen mit Gamma-Hydroxybuttersäure. Berlin: Springer-Verlag; 1978:55–65.
  • Tunstall ME. Placental transfer of 4-hydroxybutyrate. Anaesthesia 1968; 23:704–705.
  • Snead OC. Gamma-hydroxybutyrate. Life Sci 1977; 20:1935–1944.
  • Snead OC, Yu RK, Huttenlocher PR. Gamma hydroxybutyrate. Correlation of serum and cerebrospinal fluid levels with electroencephalographic and behavioral effects. Neurology 1976; 26:51–56.
  • Snead OC. Gamma hydroxybutyrate in the monkey. I. Electroencephalographic, behavioral, and pharmacokinetic studies. Neurology 1978; 28:636–642.
  • Bessman SP, Skolnik SJ. Gamma hydroxybutyrate and gamma butyrolactone: concentration in rat tissues during anesthesia. Science 1964; 143:1045–1047.
  • Chambliss KL, Gibson KM. Succinic semialdehyde dehydrogenase from mammalian brain: subunit analysis using polyclonal antiserum. Int J Biochem 1992; 24:1493–1499.
  • Vayer P, Mandel P, Maitre M. Conversion of gamma-hydroxybutyrate to gamma-aminobutyrate in vitro. J Neurochem 1985; 45:810–814.
  • Poldrugo F, Snead OC. 1,4-Butanediol and ethanol compete for degradation in rat brain and liver in vitro. Alcohol 1986; 3:367–370.
  • Quang LS, Desai MC, Shannon MW, Woolf AD, Maher TJ. 4-methylpyrazole decreases 1,4-butanediol toxicity by blocking its in vivo biotransformation to gamma-hydroxybutyric acid. Ann N Y Acad Sci 2004; 1025:528–537.
  • Mégarbane B, Fompeydie D, Garnier R, Baud FJ. Treatment of a 1,4-butanediol poisoning with fomepizole. J Toxicol Clin Toxicol 2002; 40:77–80.
  • Roth RH, Giarman NJ. Preliminary report on the metabolism of gamma-butyrolactone and gamma-hydroxybutyric acid. Biochem Pharmacol 1965; 14:177–178.
  • Roth RH. Dependence of rat serum lactonase upon calcium. Biochem Pharmacol 1967; 16:596–598.
  • Arena C, Fung HL. Absorption of sodium gamma-hydroxybutyrate and its prodrug gamma-butyrolactone: relationship between in vitro transport and in vivo absorption. J Pharm Sci 1980; 69:356–358.
  • Centers for Disease Control (CDC). Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. MMWR Morb Mortal Wkly Rep 1990; 39:861–863.
  • Li J, Stokes SA, Woeckener A. A tale of novel intoxication: a review of the effects of gamma-hydroxybutyric acid with recommendations for management. Ann Emerg Med 1998; 31:729–736.
  • Vickers MD. Gammahydroxybutyric acid. Int Anesthesiol Clin 1969; 7:75–89.
  • Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997; 92:89–96.
  • Piastra M, Tempera A, Caresta E, Chiaretti A, Genovese O, Zorzi G, . Lung injury from “liquid ecstasy”: a role for coagulation activation? Pediatr Emerg Care 2006; 22:358–360.
  • Al-Samarraie MS, Karinen R, Morland J, Opdal MS. Blood GHB concentrations and results of medical examinations in 25 car drivers in Norway. Eur J Clin Pharmacol 2010; 66:987–998.
  • Gunja N, Doyle E, Carpenter K, Chan OT, Gilmore S, Browne G, Graudins A. Gamma-hydroxybutyrate poisoning from toy beads. Med J Aust 2008; 188:54–55.
  • Hefele B, Naumann N, Trollmann R, Dittrich K, Rascher W. Fast-in, fast-out. Lancet 2009; 373:1398.
  • Ragg M. Gamma hydroxy butyrate overdose. Emerg Med (Fremantle) 1997; 9:29–31.
  • Ross TM. Gamma hydroxybutyrate overdose: two cases illustrate the unique aspects of this dangerous recreational drug. J Emerg Nurs 1995; 21:374–376.
  • Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ, Peacock EA. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 2001; 344:87–94.
  • Ortmann LA, Jaeger MW, James LP, Schexnayder SM. Coma in a 20-month-old child from an ingestion of a toy containing 1,4-butanediol, a precursor of gamma-hydroxybutyrate. Pediatr Emerg Care 2009; 25:758–760.
  • Ingels M, Rangan C, Bellezzo J, Clark RF. Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med 2000; 19:47–50.
  • Williams H, Taylor R, Roberts M. Gamma-hydroxybutyrate (GHB): a new drug of misuse. Ir Med J 1998; 91:56–57.
  • Dyer JE. Gamma-hydroxybutyrate: a health-food product producing coma and seizurelike activity. Am J Emerg Med 1991; 9:321–324.
  • Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992; 156:380–384.
  • Viswanathan S, Chen C, Kolecki P. Revivarant (gamma-butyrolactone) poisoning. Am J Emerg Med 2000; 18:358–359.
  • Osterhoudt KC, Henretig FM. Comatose teenagers at a party: what a tangled ‘Web’ we weave. Pediatr Case Rev 2003; 3:171–173.
  • Shannon M, Quang LS. Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. Pediatr Emerg Care 2000; 16:435–440.
  • Caldicott DG, Kuhn M. Gamma-hydroxybutyrate overdose and physostigmine: teaching new tricks to an old drug? Ann Emerg Med 2001; 37:99–102.
  • Runnacles JL, Stroobant J. [gamma]-Hydroxybutyrate poisoning: poisoning from toy beads. BMJ 2008; 336:110.
  • Price PA, Schachter M, Smith S, Baxter RC, Parkes JD. gamma-Hydroxybutyrate in narcolepsy. Ann Neurol 1981; 9:198.
  • Luby S, Jones J, Zalewski A. GHB use in South Carolina. Am J Public Health 1992; 82:128.
  • Yates SW, Viera AJ. Physostigmine in the treatment of gamma-hydroxybutyric acid overdose. Mayo Clin Proc 2000; 75:401–402.
  • Libetta C. Gamma hydroxybutyrate poisoning. J Accid Emerg Med 1997; 14:411.
  • Savage T, Khan A, Loftus BG. Acetone-free nail polish remover pads: toxicity in a 9-month old. Arch Dis Child 2007; 92:371.
  • Centers for Disease Control and Prevention (CDC). Adverse events associated with ingestion of gamma-butyrolactone—Minnesota, New Mexico, and Texas, 1998–1999. MMWR Morb Mortal Wkly Rep 1999; 48:137–140.
  • Robert R, Eugène M, Frat JP, Rouffineau J. Diagnosis of unsuspected gamma hydroxy-butyrate poisoning by proton NMR. J Toxicol Clin Toxicol 2001; 39:653–654.
  • Winickoff JP, Houck CS, Rothman EL, Bauchner H. Verve and jolt: deadly new Internet drugs. Pediatrics 2000; 106:829–831.
  • Lenz D, Rothschild MA, Kroner L. Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gamma-hydroxybutyric acid and gamma-butyrolactone. Ther Drug Monit 2008;30: 755–761.
  • Lora-Tamayo C, Tena T, Rodriguez A, Sancho JR, Molina E. Intoxication due to 1,4-butanediol. Forensic Sci Int 2003; 133: 256–259.
  • Higgins TFJ, Borron SW. Coma and respiratory arrest after exposure to butyrolactone. J Emerg Med 1996; 14:435–457.
  • Yambo CM, McFee RB, Caraccio TR, McGuigan M. The inkjet cleaner “Hurricane”–another GHB recipe. Vet Hum Toxicol 2004; 46:329–330.
  • Suner S, Szlatenyi CS, Wang RY. Pediatric gamma hydroxybutyrate intoxication. Acad Emerg Med 1997; 4:1041–1045.
  • Krul J, Girbes AR. Gamma-hydroxybutyrate: experience of 9 years of gamma-hydroxybutyrate (GHB)-related incidents during rave parties in The Netherlands. Clin Toxicol (Phila) 2011; 49:311–315.
  • Zvosec DL, Smith SW. Agitation is common in gamma-hydroxybutyrate toxicity. Am J Emerg Med 2005; 23:316–320.
  • Elliott S. Nonfatal instances of intoxication with gamma-hydroxybutyrate in the United Kingdom. Ther Drug Monit 2004; 26:432–440.
  • Tancredi DN, Shannon MW. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30–2003. A 21-year-old man with sudden alteration of mental status. N Engl J Med 2003; 349:1267–1275.
  • Cisek J. Seziure associated with Butanediol ingestion. Int J Med Toxicol 2001; 4:12.
  • Couper FJ, Logan BK. Determination of gamma-hydroxybutyrate (GHB) in biological specimens by gas chromatography—mass spectrometry. J Anal Toxicol 2000;24:1–7.
  • Hardy CJ, Slifman NR, Klontz KC, Dyer JE, Coody GL, Love LA. Adverse events reported with the use of gamma butyrolactone products marketed as dietary supplements [abstract]. Clin Toxicol (Phila) 1999; 37:649–650.
  • Virtue RW, Lund LO, Beckwitt HJ, Vogel JH. Cardiovascular reactions to gamma hydroxybutyrate in man. Can Anaesth Soc J 1966; 13:119–123.
  • Geldenhuys FG, Sonnendecker EW, De Klrk MC. Experience with sodium-gamma-4-hydroxybutyric acid (gamma-OH) in obstetrics. J Obstet Gynaecol Br Commonw 1968; 75:405–413.
  • Tunstall ME. Gamma-OH in anesthesia for caesarean section. Proc R Soc Med 1968; 61:827–830.
  • Hunter AS, Long WJ, Ryrie CG. An evaluation of gamma-hydroxybutyric acid in paediatric practice. Br J Anaesth 1971; 43:620–628.
  • Laborit H. Soduim 4-Hydroxybutyrate. Int J Neuropharmacol 1964; 3:433–451.
  • Piastra M, Barbaro R, Chiaretti A, Tempera A, Pulitanò S, Polidori G. Pulmonary oedema caused by “liquid ecstasy” ingestion. Arch Dis Child 2002; 86:302–303.
  • Jones C. Suspicious death related to gamma-hydroxybutyrate (GHB) toxicity. J Clin Forensic Med 2001; 8:74–76.
  • Brown TC. Gammahydroxybutyrate in paediatric anaesthesia. Aust N Z J Surg 1970; 40:94–99.
  • Win BH, Baselt RC. Apparent suicide with Renewtrient. J Toxicol Clin Toxicol 2000; 38:809.
  • Zvosec DL, Smith SW, Hall BJ. Three deaths associated with use of Xyrem. Sleep Med 2009; 10:490–493.
  • Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE. Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med 2011; 29:319–332.
  • Timby N, Eriksson A, Bostrom K. Gamma-hydroxybutyrate associated deaths. Am J Med 2000; 108:518–519.
  • Kugelberg FC, Holmgren A, Eklund A, Jones AW. Forensic toxicology findings in deaths involving gamma-hydroxybutyrate. Int J Legal Med 2010; 124:1–6.
  • Akins BE, Miranda E, Lacy JM, Logan BK. A multi-drug intoxication fatality involving Xyrem (GHB). J Forensic Sci 2009; 54:495–496.
  • Caldicott DGE, Chow FY, Burns BJ, Felgate PE, Byard RW. Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia. Med J Aust 2004; 181:310–313.
  • McCabe ER, Layne EC, Sayler DF, Slusher N, Bessman SP. Synergy of ethanol and a natural soporific—gamma hydroxybutyrate. Science 1971; 171:404–406.
  • Lettieri JT, Fung HL. Evaluation and development of gas chromatographic procedures for the determination of gamma-hydroxybutyric acid and gamma-butyrolactone in plasma. Biochem Med 1978; 20:70–80.
  • Elian AA. GC-MS determination of gamma-hydroxybutyric acid (GHB) in blood. Forensic Sci Int 2001; 122:43–47.
  • McCusker RR, Paget-Wilkes H, Chronister CW, Goldberger BA. Analysis of gamma-hydroxybutyrate (GHB) in urine by gas chromatography-mass spectrometry. J Anal Toxicol 1999; 23:301–305.
  • Mesmer MZ, Satzger RD. Determination of Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL) by HPLC/UV-VIS Spectrophotometry and HPLC/Thermospray Mass Spectrometry. J Forensic Sci 1998; 43:489–492.
  • Marinetti LJ, Isenschmid DS, Hepler BR, Kanluen S. Analysis of GHB and 4-methyl-GHB in postmortem matrices after long-term storage. J Anal Toxicol 2005; 29:41–47.
  • Kintz P, Villain M, Cirimele V, Ludes B. GHB in postmortem toxicology. Discrimination between endogenous production from exposure using multiple specimens. Forensic Sci Int 2004; 143:177–181.
  • Jones AW, Holmgren A, Kugelberg FC. Gamma-hydroxybutyrate concentrations in the blood of impaired drivers, users of illicit drugs, and medical examiner cases. J Anal Toxicol 2007; 31:566–572.
  • Ferrara SD, Tedeschi L, Frison G, Castagna F, Gallimberti L, Giorgetti R, . Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry. J Pharm Biomed Anal 1993; 11:483–487.
  • Quang LS. GHB and related compounds. In: Shannon MW, Borron SW, Burns MJ, eds. Haddad and Winchester's clinical management of poisoning and drug overdose. 4th ed. Philadelphia (PA): Saunders; 2007:803–823.
  • Elliott SP. Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production. Forensic Sci Int 2003; 133:9–16.
  • Elliott SP. Further evidence for the presence of GHB in postmortem biological fluid: implications for the interpretation of findings. J Anal Toxicol 2004; 28:20–26.
  • Elliott S. The presence of gamma-hydroxybutyric acid (GHB) in postmortem biological fluids. J Anal Toxicol 2001; 25:152.
  • LeBeau MA, Montgomery MA, Morris-Kukoski C, Schaff JE, Deakin A. Further evidence of in vitro production of gamma-hydroxybutyrate (GHB) in urine samples. Forensic Sci Int 2007; 169:152–156.
  • Chyka PA, Seger D, Krenzelok EP, Vale JA. Position paper: single dose activated charcoal. Clin Toxicol (Phila) 2005; 43:61–87.
  • Wood DM, Brailsford AD, Dargan PI. Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal 2011; 3:417–425.
  • Williams SR. Gamma-hydroxybutyric acid poisoning. West J Med 1998; 168:187–188.
  • Joint Formulary Committee. British National Formulary 59. London: Pharmaceutical Press; 2010.
  • Shah AS, Eddleston M. Should phenytoin or barbiturates be used as second-line anticonvulsant therapy for toxicological seizures? Clin Toxicol (Phila) 2010; 48:800–805.
  • Teter CJ, Guthrie SK. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy 2001; 21:1486–1513.
  • Holmes CM, Henderson RS. The elimination of pollution by a non inhalational technique. Anaesth Intensive Care 1978; 6:120–124.
  • Traub SJ, Nelson LS, Hoffman RS. Physostigmine as a treatment for gamma-hydroxybutyrate toxicity: a review. J Toxicol Clin Toxicol 2002; 40:781–787.
  • Zvosec DL, Smith SW, Litonjua R, Westfal RE. Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review. Clin Toxicol (Phila) 2007; 45:261–265.
  • Persson B, Henning M. Central cardiovascular effects of gamma-hydroxybutyric acid: interactions with noradrenaline, serotonin, dopamine and acetylcholine transmission. Acta Pharmacol Toxicol (Copenh) 1980; 47:335–346.
  • Sethy VH, Roth RH, Walters JR, Marini J, Van Woert MH. Effect of anesthetic doses of gamma-hydroxybutyrate on the acetylcholine content of rat brain. Naunyn Schmiedebergs Arch Pharmacol 1976; 295:9–14.
  • Bania TC, Chu J. Physostigmine does not effect arousal but produces toxicity in an animal model of severe gamma-hydroxybutyrate intoxication. Acad Emerg Med 2005; 12:185–189.
  • Mullins ME, Dribben W. Physostigmine treatment of gamma-hydroxybutyric acid overdose: appropriate or inappropriate use of a reversal agent? Mayo Clin Proc 2000; 75:871–872.
  • Boyer EW, Quang L, Woolf A, Shannon M. Use of physostigmine in the management of gamma-hydroxybutyrate overdose. Ann Emerg Med 2001; 38:346.
  • Feigenbaum JJ, Howard SG. Naloxone reverses the inhibitory effect of gamma-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis study. Neurosci Lett 1996; 218:5–8.
  • Devoto P, Colombo G, Cappai F, Gessa GL. Naloxone antagonizes ethanol- but not gamma-hydroxybutyrate-induced sleep in mice. Eur J Pharmacol 1994; 252:321–324.
  • Thomas G, Bonner S, Gascoigne A. Coma induced by abuse of gamma-hydroxybutyrate (GBH or liquid ecstasy): a case report. BMJ 1997; 314:35–36.
  • Lee DC, Satz WA, Dougherty T, Greene T. An investigation of flumazenil to antagonize gamma-hydroxybutyrate intoxication in a murine model. J Med Toxicol 2006; 2:68–70.
  • Schmidt-Mutter C, Pain L, Sandner G, Gobaille S, Maitre M. The anxiolytic effect of gamma-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil. Eur J Pharmacol 1998; 342:21–27.
  • Carai MA, Colombo G, Quang LS, Maher TJ, Gessa GL. Resuscitative treatments on 1,4-butanediol mortality in mice. Ann Emerg Med 2006; 47:184–189.
  • Carai MA, Colombo G, Gessa GL. Resuscitative effect of a gamma-aminobutyric acid B receptor antagonist on gamma-hydroxybutyric acid mortality in mice. Ann Emerg Med 2005; 45:614–619.
  • Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001; 37:147–153.
  • Galloway GP, Frederick SL, Staggers F. Physical dependence on sodium oxybate. Lancet 1994; 343:57.
  • Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. CJEM 2008; 10:69–74.
  • McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004; 75:3–9.
  • van Noorden MS, van Dongen L, Zitman FG, Vergouwen T. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen Hosp Psychiatry 2009; 31:394–396.
  • Miglani JS, Kim KY, Chahil R. Gamma-hydroxy butyrate withdrawal delirium: a case report. Gen Hosp Psychiatry 2000; 22:213–215.
  • Hutto B, Fairchild A, Bright R. Gamma-hydroxybutyrate withdrawal and chloral hydrate. Am J Psychiatry 2000; 157:1706.
  • Craig K, Gomez HF, McManus JL, Bania TC. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000; 18:65–70.
  • Gonzalez A, Nutt DJ. Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 2005; 19:195–204.
  • Hernandez M, McDaniel CH, Costanza CD, Hernandez OJ. GHB-induced delirium: a case report and review of the literature of gamma hydroxybutyric acid. Am J Drug Alcohol Abuse 1998; 24:179–183.
  • Catalano MC, Glass JM, Catalano G, Burrows SL, Lynn WA, Weitzner BS. Gamma butyrolactone (GBL) withdrawal syndromes. Psychosomatics 2001; 42:83–88.
  • Bowles TM, Sommi RW, Amiri M. Successful management of prolonged gamma-hydroxybutyrate and alcohol withdrawal. Pharmacotherapy 2001; 21:254–257.
  • Mahr G, Bishop CL, Orringer DJ. Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. Psychosomatics 2001; 42:439–440.
  • McDaniel CH, Miotto KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs 2001; 33:143–149.
  • Schneir AB, Ly HT, Clark RF. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med 2001; 21:31–33.
  • Sivilotti MLA, Burns MJ, Aaron CK, Greenberg MJ. Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med 2001; 38:660–665.
  • Perez E, Chu J, Bania T. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Ann Emerg Med 2006; 48:219–220.
  • Zepf FD, Holtmann M, Duketis E, Maier J, Radeloff D, Wagner A, . A 16-year-old boy with severe gamma-butyrolactone (GBL) withdrawal delirium. Pharmacopsychiatry 2009; 42: 202–203.
  • Bennett WRM, Wilson LG, Roy-Byrne PP. Gamma-hydroxybutyric acid (GHB) withdrawal: a case report. J Psychoactive Drugs 2007; 39:293–296.
  • Rosenberg MH, Deerfield LJ, Baruch EM. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for management. Am J Drug Alcohol Abuse 2003; 29:487–496.
  • Friedman J, Westlake R, Furman M. “Grievous bodily harm”: gamma hydroxybutyrate abuse leading to a Wernicke-Korsakoff syndrome. Neurology 1996; 46:469–471.
  • Bell J, Collins R. Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction 2011; 106:442–447.
  • Addolorato G, Caputo F, Capristo E, Bernardi IM, Stefanini GF, Gasbarrini G. A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: utility of diazepam administration. Clin Neuropharmacol 1999; 22:60–62.
  • Mycyk MB, Wilemon C, Aks SE. Two cases of withdrawal from 1,4-Butanediol use. Ann Emerg Med 2001; 38:345–346.
  • Herold AH, Sneed KB. Treatment of a young adult taking gamma-butyrolactone (GBL) in a primary care clinic. J Am Board Fam Pract 2002; 15:161–163.
  • Chew G, Fernando A. Epileptic seizure in GHB withdrawal. Australas Psychiatry 2004; 12:410–411.
  • LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care 2008; 8:430–433.
  • Mullins ME, Fitzmaurice SC. Lack of efficacy of benzodiazepines in treating gamma-hydroxybutyrate withdrawal. J Emerg Med 2001; 20:418–420.
  • Price G. In-patient detoxification after GHB dependence. Br J Psychiatry 2000; 177:181.
  • Dyer JE, Andrews KM. Gamma hydroxybutyrate withdrawal [abstract]. J Toxicol Clin Toxicol 1997; 35:553–554.
  • Maccioli GA. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology 2003; 98:575–577.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.